Very Early Molecular Response At 1 Month Is A Predictor Of The Outcome Of Chronic Phase Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

Background The early molecular response (EMR) by tyrosine kinase inhibitors (TKIs) is important to predict optimal response and survival in chronic phase chronic myeloid leukemia (CML-CP). However, EMR achievement can be affected by various clinical factors such as dose intensity, adverse events, blood level and risk scores. However, innate intrinsic sensitivity to TKIs of CML clones has not been considered.